- Home
- CLLS vs VKI Comparison
CLLS vs VKI Comparison
Compare CLLS & VKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | VKI |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.5M | 405.4M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | VKI |
|---|---|---|
| Price | $4.23 | $9.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 102.1K | ★ 112.8K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,551,000.00 | N/A |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $7.07 |
| 52 Week High | $5.48 | $8.98 |
Technical Indicators
Market Signals| Indicator | CLLS | VKI |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 67.05 |
| Support Level | $4.37 | $9.07 |
| Resistance Level | $4.68 | $9.15 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 6.97 | 88.14 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About VKI Invesco Advantage Municipal Income Trust II of Beneficial Interest (DE)
Invesco Advantage Municipal Income Trust II is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.